stockrow
Monday 9 November 2026
Export CUVL’s income statement to Excel — free account
Clinuvel Pharmaceuticals Ltd. - Sponsored ADR
CUVL
5.10
0.08
+1.59%
Follow CUVL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | 0.47 | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | 50 | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 104 | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Clinuvel Pharmaceuticals Ltd. - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings Inc. | $298.3M | — (loss-making) | — (loss-making) | +6.68% (above 0%: growing) | n/m | +59.86% (above 0%: growing) | 100.00% | (50.20%) | Compare |
| SPRY ARS Pharmaceuticals, Inc. | $280.5M | — (loss-making) | — (loss-making) | +16.03% (above 0%: growing) | n/m | +36.52% (above 0%: growing) | 0.00% | (90.62%) | Compare |
| QTTB Q32 Bio Inc. | $276.8M | 3.1× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SABS SAB Biotherapeutics, Inc. | $273.0M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RCKT Rocket Pharmaceuticals, Inc. | $261.8M | — (loss-making) | — | — | n/m | +19.16% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LCTX Lineage Cell Therapeutics, Inc. | $258.0M | — (loss-making) | — (loss-making) | −61.34% (below 0%: shrinking) | n/m | −32.40% (below 0%: shrinking) | 100.00% | (834.71%) | Compare |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR | $257.5M | — | — | — | — | — | — | — | |
| LRMR Larimar Therapeutics, Inc. | $248.3M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LXEO Lexeo Therapeutics, Inc. | $237.2M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $267.4M | — | — | −61.34% | — | +27.37% | 50.00% | 0.00% |